According to a study published in the November 6, 2024, online issue of Neurology, the medical journal of the American Academy of Neurology, older people who are sleepy during the day or lose interest in activities due to sleep issues may be more likely to develop a syndrome that can lead to dementia.

People with the syndrome walk slowly and report memory problems, but they do not have a mobility handicap or dementia. Motoric cognitive risk syndrome is a condition that can develop before dementia.

What The Study Found?

The study found that people with excessive daytime sleepiness and a lack of enthusiasm to get things done were more likely to develop the syndrome than people without those sleep-related issues. The study does not prove that these sleep-related issues cause the syndrome, it only shows an association.

“Our findings emphasize the need for screening for sleep issues,” said study author Victoire Leroy, MD, PhD, of Albert Einstein College of Medicine in the Bronx, New York. “There’s potential that people could get help with their sleep issues and prevent cognitive decline later in life.”

How Was It Conducted?

The study included 445 participants, with an average age of 76, who did not have dementia. Participants completed sleep surveys at the beginning of the trial. They were queried about memory problems, and their walking pace was measured on a treadmill at the beginning of the study and then once a year for the next three years.

The sleep assessment included questions about how frequently people had difficulties sleeping because they woke up in the middle of the night, couldn't fall asleep within 30 minutes, or felt too hot or cold, as well as whether they used sleep aids. The question to assess excessive daytime drowsiness asks how frequently people have had problems remaining awake when driving, eating meals, or were engaged in any other activity.

The Findings

In total, 177 participants fit the category of bad sleepers, whereas 268 satisfied the definition of good sleepers.

At the outset of the trial, 42 participants had motoric cognitive risk syndrome. Throughout the trial, 36 more persons got the condition.

35.5% of patients who experienced extreme daytime sleepiness and a lack of enthusiasm developed the syndrome, compared to 6.7% who did not. After accounting for other factors that could influence the risk of the syndrome, such as age, depression, and other health conditions, researchers discovered that people with excessive daytime sleepiness and a lack of enthusiasm were more than three times more likely to develop the syndrome than those who did not have those sleep-related issues.

“More research needs to be done to look at the relationship between sleep issues and cognitive decline and the role played by motoric cognitive risk syndrome,” Leroy said. “We also need studies to explain the mechanisms that link these sleep disturbances to motoric cognitive risk syndrome and cognitive decline.”

A limitation of the study is that participants reported their own sleep information, so they may not have remembered everything accurately.

The study was supported by the National Institute on Aging.

Bariatric surgery has been around for more than 50 years, yet it remains one of the most misunderstood areas of modern medicine. What started as a last resort for weight loss has grown into a highly researched and effective way to treat serious metabolic diseases. Even after all this time, the procedure is still buried under a lot of social stigma and medical myths.

Many people still avoid it, thinking it as an easy way out or something people do just for looks. However, in reality, it is a complex biological reset that targets the hormones driving obesity, rather than just making the stomach smaller.

As obesity rates climb globally, the gap between what the science says and what the public believes keeps millions from a treatment that could save their lives. Research from the American Society for Metabolic and Bariatric Surgery (ASMBS) shows that patients who choose this path can reduce their risk of an early death by 30% to 50%.

Deconstructing The Myths Of The Easy Way Out

Myth 1: Obesity is about a lack of willpower

The biggest mistake people make is thinking obesity is just a lack of discipline. In reality, the body has an internal set point that fights against long term weight loss from just dieting.

Myth 2: It is not safe

Many fear these operations are dangerous, but the reality has changed. Thanks to modern robotic tools, the complication rate is only about 4%.

Myth 3: It is a beauty treatment

While losing weight is the most obvious result, the real goal is to get healthy. This procedures is also used to treat other health conditions like Type 2 diabetes, high blood pressure, and sleep apnea.

Myth 4: There are instant results

This is not a magic fix where the person does not do anything. It requires a lifelong commitment to new eating habits, taking daily vitamins, and staying active. Without these lifestyle changes, the physical benefits the surgery provides can fade over time.

Choosing The Right Surgical Options And Clinical Outcomes

Choosing the right procedure is a decision based on a person’s specific health profile. The two most common surgeries today have been refined over decades to prioritize safety and long-term success.

1. Sleeve Gastrectomy: This is currently the most opted choice which involves removing about 80% of the stomach, which lowers the production of hunger hormones. It’s a shorter surgery with a very low complication rate.

2. Gastric Bypass: This is often considered the gold standard for treating severe Type 2 diabetes. Rerouting the small intestine, it creates a more powerful metabolic shift that helps control blood sugar almost immediately.

3. Biliopancreatic Diversion (BPD/DS): Reserved for more complex cases, this offers the highest level of weight loss and diabetes remission but requires the strictest adherence to vitamin and protein intake.

4. Long Term Durability: Unlike many temporary fixes, data shows that five to twenty years after surgery, the majority of patients maintain a significant portion of their weight loss and keep their metabolic diseases under control.

The Physiological Shift: Beyond Mechanical Restriction

In the early days, these procedures were mostly about restriction - simply making the stomach smaller so a person couldn't eat as much. Today, we know it's much more about the chemistry. When the digestive path is changed, the way the gut and brain talk to each other is completely transformed. This biochemical shift is why many see their Type 2 diabetes disappear almost immediately, sometimes even before they've lost much weight. The surgery turns down the volume on intense cravings and turns up the signals that tell the brain the body is full.

These changes also help the heart and the rest of the endocrine system. By lowering inflammation and helping the body use insulin better, the risk of heart attacks and strokes drops significantly.

The benefits aren't just about a smaller number on the scale; it’s about a total change in how the body handles energy. This allows a person to maintain a healthier weight because their body is no longer fighting against them, thinking it’s starving.

Societal Barriers And The Future Of Metabolic Health

The reason these myths stick around is because society tends to judge people based on their weight. When obesity is treated as a character flaw instead of a chronic illness, surgery is seen as a shortcut. But for someone with a Body Mass Index (BMI) over 40, the chances of reaching a healthy weight through lifestyle changes alone is less than 1%.

With the advancement in technology, we need to stop talking about weight loss and start talking about metabolic health. We are moving toward early access, which means treating metabolic issues before they cause permanent damage to the heart or kidneys. Clearing up these 50-year-old myths isn't just about setting the record straight, it’s a necessary step for public health.

An interesting yet alarming trend is being observed in people who are losing weight with Mounjaro, loose skin, or popularly known as Mounjaro Face.

Post Mounjaro/Ozempic, many patients are now reporting a face that’s saggy or making them look 10 years older.

Mounjaro Face

Neha, a 34-year-old MNC executive who came to us saying, “Doc, now that I have Zoom calls and everything, I’ve lost almost 20–30 kgs in the last 9 months. My weight has plateaued, but one thing I have noticed is that I have that ‘Mounjaro/ Ozempic face,’ which I read in one of the newspaper articles.”

“Ozempic face” or “Mounjaro face” is becoming pretty common nowadays. The problem lies in the fact that the facial volume has been reduced.

The looseness of the skin accentuates the effects of weight loss. It also depends on the age and genetics of an individual. Usually, patients who are taking high doses of Mounjaro and have lost significant weight in a short span are more susceptible to facial changes like looseness of skin and loss of volume.

Why Does It Happen?

Mounjaro or Ozempic are semaglutides, which are GLP-1 agonists that act on the body to deplete body fat. It also has an impact on facial compartments, which have facial fat, include superficial and deep fat that support the face.

When these compartments are depleted of fat, it shows as hollowness, especially in the under-eye region or the cheek region. You may have a sharp jawline, but with saggy skin.

After 40 years, older patients have less collagen and elastin, so they adapt poorly to fat loss and therefore, the extent can be prominent. Also, faster weight drops with a slimmer baseline face are affected more by it.

Vitamin, mineral, and protein deficiency, along with dehydration, can be contributory factors.

How Can I Prevent It?

Well, if you are on Ozempic or Mounjaro-like drugs, make sure your protein intake is adequate. Most doctors would like to keep it around 1.5 g to 2 g per kg body weight, depending on the patient’s health condition.

Another crucial aspect is strength training, especially to maintain muscle mass.

Essential intake of supplements like vitamins, minerals, and collagen can also help in maintaining skin structure.

If you’re experiencing early laxity of the skin, like early skin looseness or prominent nasolabial lines, then radiofrequency, MIcroneedling, HIFU, and similar technologies might work.

In some cases, fillers and threads can help you, but these are not long-term measures.

In cases where there is loss of complete elasticity, the treatment remains surgical, which, depending on the extent, can be a full or mini facelift. In this, not only is facial skin tightened, but also the deeper muscle layer is tightened. To restore the volume, many patients opt for facial fat transfer, where the body’s own fat can be used to augment lost volume in the face.

Confidence And Self-esteem

Confidence is not just about losing weight; it’s also about regaining your self-esteem.

Whenever someone is on Mounjaro or Ozempic, it is pertinent to take care of all the other factors and make sure it is properly monitored, so that your skin doesn’t sag and you don’t look older.

Metabolism-Associated Fatty Liver Disease (MAFLD) — also termed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — is defined by excess hepatic fat accumulation (>5 per cent of liver weight) in the presence of metabolic dysfunction, independent of alcohol intake. It encompasses a spectrum from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma.

MAFLD: Epidemiology In India

A Lancet Regional Health study found that approximately 39 per cent of Indian adults screened had fatty liver disease, making it one of the most prevalent chronic liver conditions in the country. Within India, prevalence shows regional variation driven by genetic, dietary, and socioeconomic factors.

A particularly important feature is the “lean MAFLD” phenotype — South Asians often develop fatty liver at a lower BMI due to disproportionately high visceral fat, which complicates detection based on conventional BMI screening. Currently, MASLD is the commonest cause of liver cirrhosis and hepatocellular carcinoma (HCC).

MAFLD: Causes And Risk Factors

The core drivers are components of metabolic syndrome: type 2 diabetes mellitus, obesity (particularly central adiposity), dyslipidemia, hypertension, and insulin resistance. MASLD is strongly linked to obesity, sedentary lifestyles, and metabolic syndrome.

Genetic susceptibility also plays a role — variants in genes such as PNPLA3 are associated with increased liver fat accumulation, particularly in certain Indian populations. Rapid dietary transition towards ultra-processed, high-calorie foods compounds the risk.

MAFLD: Investigations

Routine liver function tests may appear normal in early stages, and an ultrasound detects only moderate-to-severe fat accumulation. A structured approach includes:

• Blood tests: LFTs, fasting glucose, HbA1c, lipid profile, insulin resistance indices
• Ultrasound abdomen: First-line imaging for steatosis
• FibroScan (Transient Elastography): Liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) are standardized non-invasive tools for assessing fibrosis and steatosis.
• Liver biopsy: Gold standard for staging steatohepatitis and fibrosis when non-invasive tests are inconclusive.

MAFLD: Treatment

No approved pharmacotherapy exists exclusively for MAFLD; management is lifestyle-centred:

• Weight loss: 7–10 per cent body weight reduction significantly reduces hepatic steatosis and inflammation
• Diet: Mediterranean-style diet; restrict refined carbohydrates and saturated fats
• Exercise: Both aerobic and resistance training improve insulin sensitivity and liver fat
• Metabolic comorbidity control: Optimise glycaemia (GLP-1 agonists show hepatic benefit), manage dyslipidaemia and hypertension
• Emerging therapies: Resmetirom (thyroid hormone receptor-β agonist) has shown promise in MASH with fibrosis.